TiGenix selects TFS for first clinical trial to treat severe sepsis with allogeneic expanded adipose
TiGenix has selected TFS International (TFS) for the first clinical trial (SEPCELL) to use stem cell therapy in the treatment of severe sepsis secondary to severe community acquired pneumonia (sCAP).
The SEPCELL project is a randomized, double-blind, placebo-controlled, Phase Ib/IIa study in severe sepsis secondary to severe CAP (sCAP).
Subjects in the trial must have sCAP requiring mechanical ventilation and/or vasopressors. The trial is expected to enroll 180 patients, and will be conducted at approximately 50 centers throughout Europe.
Click on this link for more information.
